Barbara Depreter

Dr. Barbara Depreter


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2026 in Blood
Verified
Journal Article
Closed access
JCJacqueline Cloos
Jacqueline Cloos
PVPeter J.M. Valk
Peter J.M. Valk
CTChristian Thiede
Christian Thiede
KDKonstanze Döhner
Konstanze Döhner
GRGail J. Roboz
Gail J. Roboz
MHMichael Heuser
Michael Heuser
Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key end point in clinical trials. The 2025 update of the MRD guideline provides a comprehensive and refined framework for MRD assessment, aligned with the European LeukemiaNet (ELN) 2022 genetic risk classification. Developed by members of the ELN AML MRD Working Party, the guidelines incorporate expert consensus determined through a 2-stage Delphi round. They address the clinical implementation of MRD methodologies, technical considerations, integration into clinical trials, and future directions. Importantly, MRD recommendations are tailored to individual prognostic and genetic subgroups. A new qualitative MRD response category, designated as optimal, warning, or high risk of treatment failure, has been introduced to facilitate contextual interpretation of the MRD burden and its clinical relevance. Notably, ultrahigh-sensitivity next-generation sequencing–based MRD assessment is now recommended for FLT3 internal tandem duplication–mutated AML after intensive chemotherapy and before allogeneic hematopoietic cell transplantation. A total of 56 recommendations were formulated, with 53 achieving a high level of consensus (≥90%). These updated guidelines represent a major step forward toward harmonizing MRD assessments in AML and enhancing its clinical utility across diverse treatment settings.

17 October 2020 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
BDBarbara Depreter
Barbara Depreter
BMBarbara De Moerloose
Barbara De Moerloose
KVKarl Vandepoele
Karl Vandepoele
AUAnne Uyttebroeck
Anne Uyttebroeck
ADAn Van Damme
An Van Damme
TLTim Lammens
Tim Lammens

11 September 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
SDSimke Demeester
Simke Demeester
TDThomas Demuyser
Thomas Demuyser
CFCharlotte Fauconnier
Charlotte Fauconnier
RHRobbe Heestermans
Robbe Heestermans
COChristelle Orlando
Christelle Orlando
KJKristin Jochmans
Kristin Jochmans
Click on the article title to read more.

2 November 2017 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
BDBarbara Depreter
Barbara Depreter
JPJan Philippé
Jan Philippé
MMMagali Meul
Magali Meul
BDBarbara Denys
Barbara Denys
KVKarl Vandepoele
Karl Vandepoele
TLTim Lammens
Tim Lammens

Verified
Journal Article
Open access
PDF file
JVJolien Vanhooren
Jolien Vanhooren
LDLarissa Deneweth
Larissa Deneweth
Luca PagliaroLuca Pagliaro
Luca Pagliaro
ZRZhiyao Ren
Zhiyao Ren
MGMariateresa Giaimo
Mariateresa Giaimo
TLTim Lammens
Tim Lammens
Despite advances in outcome, one third of children with acute myeloid leukemia (AML) relapse, and less than half will achieve long-term survival. Relapse in AML has been shown to be driven in part by leukemic stem cells (LSCs), highlighting the unmet medical need to better characterize and target this therapy-resistant cell population. Micro-array profiling of pediatric AML subpopulations (LSCs and leukemic myeloblasts) and their healthy counterparts revealed nidogen-1 (NID1) as expressed in both leukemic subpopulations while absent in the hematopoietic stem cell. Using the TARGET dataset including pediatric AML patients (n = 1025), NID1 expression showed a correlation with worse event-free survival and KMT2A rearrangements. Drug response profiling of a NID1 knockdown model demonstrated differential sensitivity to HSP90 inhibition. RNA sequencing and gene set enrichment analysis between NID1high and NID1low phenotypes showed involvement of NID1 in mitochondrial metabolic pathways known to be enriched in LSCs. Altogether, this study highlights NID1 as a novel oncogene associated with worse EFS and metabolic LSC phenotype in AML. NID1 could serve as a biomarker and aid in further mapping LSCs to establish therapeutic strategies tackling the high relapse rates in pediatric AML.

13 November 2019 in Blood
Verified
Journal Article
Open access
BDBarbara Depreter
Barbara Depreter
MHMattias Hofmans
Mattias Hofmans
ETEva Terras
Eva Terras
AUAnne Uyttebroeck
Anne Uyttebroeck
ADAn Van Damme
An Van Damme
TLTim Lammens
Tim Lammens
Introduction and Aim Although cytogenetics and response-guided therapy have considerably improved prognostication of pediatric AML (pedAML) patients, still 30-40% of the good responders relapse. Further delineation of the transcriptome of AML subpopulations, e.g. leukemic stem cells (LSCs), might result in a better understanding of pedAML biology and provide novel biomarkers for diagnostics, risk stratification, follow-up and targeted therapy. Methods Fluorescence-activated cell sorting (FACS) was used to isolate CD34+CD38- and CD34+CD38+ cells from pedAML patients/healthy controls (cord blood (CB), normal bone marrow (NBM)), defined as LSC/hematopoietic stem cell (HSC) and leukemic blast (L-blast)/control blast (C-blast), respectively. Sorting multiple phenotypes, both BM and blood, yielded 42 LSC and 35 L-blast fractions. Gene expression profiles (GEP) of LSCs and L-blasts were identified by a Cancer vs Normal (CvN) approach, whereas paired analysis of LSC vs L-blast aimed to identify LSC-specific aberrations. Micro-array analysis (4 pedAML, 3 CB) was followed by targeted quantitative PCR (qPCR) validation of the highest differentially expressed genes (DEGs) in LSC (n=52), L-blast (n=42) and between LSC and L-blast (n=15) (25 pedAML, 11 CB/9 NBM). DEGs were functionally analysed by protein association (STRING) and by gene set enrichment analysis (GSEA-Cytoscape). An overview of the workflow is shown in Fig. 1A. Results LSC vs HSC micro-array analysis revealed 83 up- and 212 downregulated targets (Fig. 1B). qPCR confirmed 8 and 11 of the 52 tested targets to be highly significantly up- and downregulated, respectively, in LSC (n=42) compared to HSC (n=20) (P<.001). Overexpressed targets contained well-known oncogenes (e.g. CFD, ANXA2, EMP1), next to genes with undefined roles in AML (e.g. PLIN2, CRIP1). Six out of the top 30 downregulated DEGs were described as tumor suppressor genes (TSGs) in solid tumors. Functional protein associations showed enriched cancer pathways, osteoclast differentiation, apoptosis and breast cancer, whereas Th17 cell differentiation and Rap1/MAPK signaling were suppressed in LSCs. LSC-enriched gene sets included inflammation, apoptosis, immune suppression and adipogenesis, while HSC-related signatures were anti-correlated. L-blasts showed 157 and 332 up- and downregulated DEGs (Fig. 1C), and 8/42 were confirmed as significantly upregulated by qPCR (L-blast=35 vs C-blast=19, P<.001) e.g. DUSP6, HOMER3 and EMP1. Functional analysis showed L-blasts to be associated with increased apoptosis and oxidative stress (FoxO signaling, cytokine-cytokine receptor interactions) compared to their normal counterparts. Gene sets enriched in LSCs vs L-blasts addressed inflammatory responses, adipogenesis, TNF signaling and response. Pathway analysis showed repression of cell cycle genes, consistent with LSC quiescence. qPCR validation of 15 out of the 117 upregulated targets (Fig. 1D), of which 5/15 had a neural link (PCDHB2, GPRIN3, SLC22A23, CDR1, RPGRIP1L), did not confirm significant dysregulated expression (P>.05). Interestingly, the set of DEGs between LSCs and L-blasts shared only few genes with those differentially expressed between HSC and C-blast (28/306; 4 up- and 24 downregulated). This low intersection (7.7%) is in strong contrast to the previously reported 34% in adult AML (Gal et al. 2006). Moreover, none of those genes were detected in adult AML (except for CD38 downregulation). Remarkably, 3/4 mutual upregulated genes (IGF2, GPRIN3, PROS1, CYTH4) are involved in neural crossroads and have no relation to stemness nor AML. Conclusion Combining FACS with CvN transcriptomic profiling, followed by qPCR validation, identified novel DEGs in pedAML subpopulations. The majority of the most significant upregulated targets in LSCs (n=8) and L-blasts (n=8) showed no previous link to pedAML. Identification of 11 novel downregulated targets, often described as TSGs in solid tumors, warrants further studies whether hypomethylating therapy could result into LSC eradication in pedAML. LSCs reflected low cell cycle activity and elevated inflammatory response, hypoxia, metabolic dysregulation and signaling compared to HSC. GEP of LSCs vs L-blasts revealed a distinct molecular landscape compared to adult AML, and suggested a possible link between distortion of neural and hematopoietic systems in leukemogenesis.